relevant to the contents of this paper to disclose. and did not have some other compelling indication for beta-blocker use (e.g., LV systolic dysfunction, prior MI, or history of heart failure). They examined the clinical outcomes of these patients at both 30 days and 3 years of follow-up based on whether or not they were prescribed a beta-blocker after a PCI. They also examined predictors and trends of beta-blocker prescriptions in these patients. patients to obtain the medication, although we lack data on overall beta-blocker adherence. However, as the authors point out, the group of patients for whom beta-blocker therapy was prescribed had a higher prevalence of traditional cardiovascular risk factors, and hence it is quite possible that these subjects were prescribed a beta-blocker after PCI because of more complex anatomic CAD or an incomplete revascularization. In those cases, the treating physician also may have been concerned about the potential for ongoing ischemia. Considering these possibilities, one may interpret these data from the perspective that the use of beta-blocker therapy was effective therapeutically, because the patients in that group did not have a higher incidence of ischemic events. Finally, why there was an increased rate of hospitalization due to heart failure in the group discharged on beta-blockers is unclear, although this finding was likewise observed by Bangalore and colleagues who also found an increased incidence of heart failure in patients treated with beta-blockers in the reperfusion era (3). These findings from 2 studies suggest that there may be competing mechanisms of benefit and potential harm associated with beta-blocker usage in SIHD patients without prior MI or LV dysfunctionwhich perhaps may be another reason for a more cautious, selective use of these agents.
In conclusion, this study along with others (9, 10, 19) , 
